drugset / Trial / NCT03726515
CART-EGFRvIII + Pembrolizumab in GBM
NaSingle-groupOpen-labelTreatment
Summary
This is an open-label, phase 1 study to assess the safety and tolerability of EGFRvIII T cells in combination with pembrolizumab (PD-1 Inhibitor) in patients with newly diagnosed, EGFRvIII+, MGMT-unmethylated glioblastoma.
Timeline
- Start
- 2019-03-11
- Primary completion
- 2021-02-27
- Completion
- 2021-02-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CART-EGFRvIII T cells | Cell therapy | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |